类风湿关节炎血清趋化因子 RNAKL及25-羟维生素D水平与疾病进展的相关性分析

doi:10.3969/j.issn.1006-6233.2022.11.013

Abstract
Figure/Table
References
Related Citation (13)

Download: PDF (1205 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the correlation of serum chemokine, RNAKL and 25- hydroxy vitamin D [25(OH)D] levels with disease progression in rheumatoid arthritis.Methods: 289 patients with rheumatoid arthritis diagnosed and treated in our hospital from January 2019 to December 2021, and 100 healthy subjects who underwent physical examination in our hospital simultaneously, were included for the study. RA patients were divided into RA remission group and RA activity group using disease activity score 28-jointcount. Fasting serum levels of C-C chemokine ligand 20 (CCL20), RNAKL and 25(OH)D were determined in RA patients and healthy subjects.And DAS28 score was used as a variable of RA disease progression to analyze the correlation between the above indicators and RA disease progression. Results: Compared with the control group, the serum levels of CCL20 and RNAKL in RA patients were significantly increased, while the level of 25(OH)D was significantly decreased, the difference was statistically significant(P<0.05). Serum levels of CCL20 and RNAKL in RA activity group were significantly higher than those in RA remission group, the difference was statistically significant(P<0.05). Serum 25(OH)D levels in RA activity group were significantly lower than those in RA remission group, the difference was statistically significant(P<0.05). Using DAS28 score as a variable for RA disease progression, correlation analysis showed that serum CCL20 and RNAKL levels were positively correlated with the DAS28 score (P<0.05), while serum 25(OH)D levels were negatively correlated with the DAS28 score (P<0.05). Conclusion: Serum levels of CCL20, RNAKL and 25(OH)D are correlated with the progression of RA, and CCL20, RNAKL and 25(OH)D can be used as biological indicators to monitor disease activity and assist doctors to judge patients' conditions comprehensively.

Key words： Rheumatoid arthritis Serum chemokine RNAKL 25- hydroxy vitamin D

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2022.11.013 OR http://www.hbyxzzs.cn/EN/Y2022/V28/I11/1826

[1] 罗采南,李正芳,武丽君,等.类风湿关节炎不同分类标准的多中心临床比较[J].北京大学学报(医学版),2020,52(5):897-901.
[2] 陈旭艳,王青青,伊雪,等.TNF-α拮抗剂对激素联合环磷酰胺治疗类风湿关节炎合并间质性肺病疗效的影响[J].河北医学,2021,27(5):723-727.
[3] 俞烜华,黄惠娟,李扬宇.纤维蛋白原、纤维蛋白(原)降解产物、D-二聚体与类风湿关节炎疾病活动指标的关系[J].中国医学创新,2019,35(35):57-61.
[4] 李倩,吴雍真,柴艺汇,等.类风湿关节炎中免疫细胞与维生素D的相关性探讨[J].风湿病与关节炎,2020,9(12):46-49.
[5] Classification of rheumatoid arthritis: comparison of the 1987 American college of rheumatology criteria and the 2010 American college of rheumatology/European league against rheumatism criteria[A].M.P.M.van der Linden; R.Knevel; T.W.J.Huizinga; A.H.Mvan der Helm-van Mil.Arthritis & Rheumatism.2010.
[6] Takanashi S,Kaneko Y,Takeuchi T.CDAI and DAS28 in the management of rheumatoid arthritis in clinical practice[J].Ann Rheum Dis,2020,79 (5):671-674.
[7] 赵蕾,陈宗涛,孙丽,等.类风湿关节炎患者骨密度与代谢关系的研究进展[J].医学综述,2020,26(24):4841-4845.
[8] 陈淑琳,林昌松.类风湿关节炎合并抗ENA抗体异常患者的中西医临床特征[J].广州中医药大学学报,2022,39(4):735-740.
[9] 陆兴热,陈凤羽,资云菊,等.抗CCP抗体、AKA和GPI抗原对类风湿关节炎的诊断价值[J].检验医学,2019,34(12):1145-1146.
[10] 张南廷,高琴,吴记平.类风湿关节炎患者血清及关节液ANGPTL4和IL-17及RANKL的表达及意义[J].当代医学,2022,28(8):108-110.
[11] 万磊,刘健,黄传兵,等.基于CD19~+B细胞调控FAK/CAPN/PI3K通路研究新风胶囊改善类风湿关节炎机制[J].中国中药杂志,2021,46(14):3705-3711.
[12] 华丽,施晓蔚,樊佳,等.25-(OH)D对早期类风湿关节炎的预测价值及与疾病活动度和免疫功能指标的相关性分析[J].中华全科医学,2020,18(3):403-407.
[13] 周艳,高洁,柴艺汇,等.维生素D在类风湿关节炎发病中的免疫机制[J].湖北民族大学学报(医学版),2020,37(1):89-92.